SCHEMBL25405152

SCHEMBL25405152

Cc1nc2c(F)cc(-c3nc(Nc4ccc(CN5CCN(CC6CNC6)CC5)cn4)ncc3F)cc2n1C(C)C

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 20/20 0.80
CDK1 P06493 17/20 0.80
CDK6 Q00534 16/20 0.80
CCND3 P30281 11/20 0.80
CCNA2 P20248 5/20 0.80
CDK2 P24941 5/20 0.80
CCNB1 P14635 4/20 0.80
CCNE1 P24864 4/20 0.80
CDK7 P50613 4/20 0.80
CDK9 P50750 4/20 0.80
CDK5 Q00535 3/20 0.80
CIT O14578 1/20 0.80
GAK O14976 1/20 0.80
DYRK3 O43781 1/20 0.80
CCNT1 O60563 1/20 0.80
STK16 O75716 1/20 0.80
CCNK O75909 1/20 0.80
STK10 O94804 1/20 0.80
PRKD3 O94806 1/20 0.80
ABCB11 O95342 1/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584557 1.00 CDK4 (0.80) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL30672851 0.93 CDK4 (0.78) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL30460094 0.90 CDK4 (0.84) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL30459468 0.90 CDK4 (0.84) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL2490067 0.90 CDK4 (0.84) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL17489046 0.89 CDK4 (0.76) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL15252470 0.89 CDK6 (0.88) CDK4CDK1CDK6CCND3CCNA2
SCHEMBL2487954 0.89 CDK6 (0.88) CDK4CDK1CDK6CCND3CCNA2
Abemaciclib SCHEMBL29356350 0.89 CDK4 (1.00) CDK4CDK1CDK6CCND3CCNA2
Abemaciclib SCHEMBL29423472 0.89 CDK4 (1.00) CDK4CDK1CDK6CCND3CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES ENDOTARGET INC. 2023-09-21 US disclosed
WO-2023177451-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES EnhancedBio Inc. (KR) 2023-09-21 WO disclosed
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES ENDOTARGET INC. 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295118-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES CDK6, CDK4, CDK1 CDK4 2/4885CDK1 3/4885CDK6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.